Cite
HARVARD Citation
He, L. et al. (2022). Clinical Efficacy of Antianlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small-Cell Lung Cancer and Its Effect on Serum VEGF, CEA, and SCC-Ag. Journal of oncology. p. . [Online].